A detailed history of Founders Capital Management transactions in Genmab A/S stock. As of the latest transaction made, Founders Capital Management holds 1,000 shares of GMAB stock, worth $22,010. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,000
Holding current value
$22,010
% of portfolio
0.01%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Jul 18, 2025

BUY
$17.98 - $23.09 $17,980 - $23,090
1,000 New
1,000 $20,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $14.5B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Founders Capital Management Portfolio

Follow Founders Capital Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Founders Capital Management, based on Form 13F filings with the SEC.

News

Stay updated on Founders Capital Management with notifications on news.